COOPER COS INC/THE
COONASDAQ🏆 #829 by market capEarnings Dec 2 · PostUS Equity
$56.44▼ $0.14 (−0.24%)
LiveTrack COO
Get earnings, price moves & breaking news on Telegram
24h▼ 0.2%
7d▲ 2.1%
14d▲ 6.0%
30d▼ 20.7%
ytd▼ 31.1%
1y▼ 16.6%
🏦Market Cap
$11.01B
Mid Cap
📈Revenue Growth (YoY)
+5.1%
Slowing
📊Gross Margin
63.6%
High
💵FCF Margin
16.0%
Healthy
⚖️P/S Ratio
2.6x
Cheap
Otter Score
80
Good
COOPER COS INC/THE
COOAnalyst Ratings
Price
$56.44
Total
28
Raised
2
Lowered
7
Avg PT
$65.75
H / L
$75 / $59
| Institution | Action | Rating | Date | Upside | |
|---|---|---|---|---|---|
Needham | Reiterated | Buy | 2026-09-15 | $73.00 | +29.30% |
Mizuho | Reiterated | Outperform | 2026-09-11 | — | — |
Piper Sandler | Downgraded | Overweight → Neutral | 2026-09-10 | $59.00 | +4.50% |
Stifel | Reiterated | Buy | 2026-09-10 | — | — |
William Blair | Downgraded | Outperform → Market Perform | 2026-09-10 | — | — |
Wells Fargo | Reiterated | Equal Weight | 2026-09-10 | $61.00 | +8.10% |
Baird | Downgraded | Outperform → Neutral | 2026-09-10 | — | — |
B of A Securities | Downgraded | Buy → Neutral | 2026-09-10 | — | — |
UBS | Reiterated | Neutral | 2026-09-10 | $66.00 | +16.90% |
Citigroup | Reiterated | Neutral | 2026-09-10 | $368.00 | +552.10% |
JP Morgan | Reiterated | Neutral | 2026-09-10 | — | — |
BNP Paribas | Reiterated | Outperform | 2026-06-08 | — | — |
Barclays | Reiterated | Overweight | 2026-03-06 | $98.00 | +73.60% |
Goldman Sachs | Reiterated | Sell | 2025-12-08 | $61.00 | +8.10% |
Morgan Stanley | Reiterated | Equal Weight | 2025-12-08 | $76.00 | +34.70% |
Redburn Atlantic | Downgraded | Buy → Neutral | 2023-10-04 | — | — |
Jefferies | Downgraded | Buy → Hold | 2022-10-11 | $115.00 | +103.80% |
Keybanc | Downgraded | Overweight → Sector Weight | 2022-08-28 | — | — |
Stephens & Co. | Reiterated | Overweight | 2022-06-02 | — | — |
Guggenheim | Upgraded | Neutral → Buy | 2022-01-02 | — | — |
KeyBanc | Reiterated | Overweight | 2021-03-05 | — | — |
Raymond James | Reiterated | Outperform | 2021-03-04 | — | — |
Oppenheimer | Reiterated | Perform | 2020-09-03 | — | — |
BMO Capital | Reiterated | Outperform | 2019-03-05 | — | — |
Cleveland Research | Upgraded | Neutral → Buy | 2016-05-15 | — | — |
PiperJaffray | Reiterated | Overweight | 2015-12-04 | — | — |
Stifel Nicolaus | Reiterated | Buy | 2015-12-01 | $70.00 | +24.00% |
Morgan Keegan | Reiterated | Outperform | 2012-03-08 | — | — |
Institution
Needham
Reiterated · Buy · 2026-09-15
$73.00
+29.30%
Mizuho
Reiterated · Outperform · 2026-09-11
—
—
Piper Sandler
Downgraded · Overweight → Neutral · 2026-09-10
$59.00
+4.50%
Stifel
Reiterated · Buy · 2026-09-10
—
—
William Blair
Downgraded · Outperform → Market Perform · 2026-09-10
—
—
Wells Fargo
Reiterated · Equal Weight · 2026-09-10
$61.00
+8.10%
Baird
Downgraded · Outperform → Neutral · 2026-09-10
—
—
B of A Securities
Downgraded · Buy → Neutral · 2026-09-10
—
—
UBS
Reiterated · Neutral · 2026-09-10
$66.00
+16.90%
Citigroup
Reiterated · Neutral · 2026-09-10
$368.00
+552.10%
JP Morgan
Reiterated · Neutral · 2026-09-10
—
—
BNP Paribas
Reiterated · Outperform · 2026-06-08
—
—
Barclays
Reiterated · Overweight · 2026-03-06
$98.00
+73.60%
Goldman Sachs
Reiterated · Sell · 2025-12-08
$61.00
+8.10%
Morgan Stanley
Reiterated · Equal Weight · 2025-12-08
$76.00
+34.70%
Redburn Atlantic
Downgraded · Buy → Neutral · 2023-10-04
—
—
Jefferies
Downgraded · Buy → Hold · 2022-10-11
$115.00
+103.80%
Keybanc
Downgraded · Overweight → Sector Weight · 2022-08-28
—
—
Stephens & Co.
Reiterated · Overweight · 2022-06-02
—
—
Guggenheim
Upgraded · Neutral → Buy · 2022-01-02
—
—
KeyBanc
Reiterated · Overweight · 2021-03-05
—
—
Raymond James
Reiterated · Outperform · 2021-03-04
—
—
Oppenheimer
Reiterated · Perform · 2020-09-03
—
—
BMO Capital
Reiterated · Outperform · 2019-03-05
—
—
Cleveland Research
Upgraded · Neutral → Buy · 2016-05-15
—
—
PiperJaffray
Reiterated · Overweight · 2015-12-04
—
—
Stifel Nicolaus
Reiterated · Buy · 2015-12-01
$70.00
+24.00%
Morgan Keegan
Reiterated · Outperform · 2012-03-08
—
—
One row per institution · price target from the firm's latest published target